Semaglutide long-acting injectable - Adocia
Alternative Names: ADOGEL® SEMALatest Information Update: 08 Dec 2023
At a glance
- Originator Adocia
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 02 Nov 2023 Semaglutide injectable - Adocia is available for licensing as of 02 Nov 2023. https://www.adocia.com/products-and-platform/pipeline/
- 02 Nov 2023 Preclinical trials in Obesity in France (Parenteral) (before November 2023) (Adocia Pipeline, November 2023)